Market Overview

Needham Is Bullish On Progenics Pharmaceuticals

Share:

Tarrytown, New Jersey-based Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) is engaged in the development of medicines for oncology. Earlier this week, the company achieved a major milestone as it submitted a New Drug Application (NDA) for oral Relistor.

Relistor is a treatment for opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The drug has been exclusively licensed to Valeant Pharmaceuticals for development and commercialization.

In a research note on Wednesday, analysts at Needham said that they see the NDA submission as a potential avenue to build market share in OIC. Needham analysts also see more value drivers for Progenics in 2016, which include enrolment for Azedra in pheochromocytoma trial to be completed by the end of this year and data possibly by the middle of 2016.

Needham analysts also expect a Phase III study for prostate cancer imaging agent 1404 to commence in 2015.

According to Needham, Azedra will be a near-term commercialization opportunity and 1404, a longer-term blockbuster opportunity for Progenics.

Needham has a Buy rating on Progenics Pharmaceuticals, with a price target of $9. The stock is currently trading at around $7.

On Wednesday, Progenics also made a presentation at Cantor Fitzgerald’s Inaugural Healthcare Conference. The presentation was made by Progenics CEO Mark Baker.

Latest Ratings for PGNX

DateFirmActionFromTo
Jul 2019Brookline CapitalInitiates Coverage OnBuy
Dec 2018Credit SuisseInitiates Coverage OnOutperform
Jul 2017Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for PGNX
View the Latest Analyst Ratings

 

Related Articles (PGNX)

View Comments and Join the Discussion!

Posted-In: Mark Baker progenicsAnalyst Color Biotech Long Ideas Analyst Ratings Trading Ideas General

Latest Ratings

StockFirmActionPT
TSLAJP MorganMaintains125.0
INTCTruist SecuritiesMaintains64.0
FBTruist SecuritiesMaintains320.0
GSCitigroupMaintains370.0
AAPLCowen & Co.Maintains153.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com